Vetaphone plots market growth

Corona treatment specialist Vetaphone is benefiting from the growth in digital, as it plans substantial growth in the years ahead.

Digital was initially predicted to have a negative effect on the corona treatment market, but Vetaphone said it has seen sales increase due to the need for treatment before and after printing to facilitate downstream product enhancement, such as cold foiling

Digital was initially predicted to have a negative effect on the corona treatment market, but Vetaphone said it has seen sales increase due to the need for treatment before and after printing to facilitate downstream product enhancement, such as cold foiling.

In 2013, it saw unit sales top 1,000 and is targeting a 25 percent increase in 2014 as part of a longer term project to achieve a 400 percent growth in sales in the years to 2016 through printing, laminating and key accounts.

This aim is being supported by corporate and technological advances. 2013 saw the launch of EASI-Plasma, with plasma a key area of growth for the company in the mid and wide web markets. Vetaphone is reportedly close to a technical breakthrough that will ‘significantly change the ground rules in the flexible packaging industry’, with an exclusive agreement with one of Europe’s top press manufacturers close to being finalized.

Jan Eisby (pictured, right), the son of Vetaphone’s founder and who now runs the company with his brother Frank, said: ‘We intend to build close working relationships with the OEMs in this market, just as we have in narrow web.  We know that our technology can significantly improve press production speed and print and lamination quality, at the same time as reducing expensive waste, and will build our growth around successful commercial installations.’

Meanwhile, a two million EUR (2.7 million USD) construction project, covering a complete refurbishment of its existing building with increased production facilities and the construction of a new building on land owned by the company, plus the appointment of eight new sales and production staff, is the largest investment program in Vetaphone’s 63-year history.

Eisby said: ‘We have taken corona treatment far beyond what was ever envisaged when my father started the company, and with our development of commercially viable EASI-Plasma treatment, we can foresee significant growth opportunities ahead.

‘We need to build on our list of end users and OEMs, and find projects from our key accounts that challenge us and allow us to develop new products.’